By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Streptogramins > Dalfopristin and quinupristin > Dalfopristin / Quinupristin Dosage
Streptogramins
https://themeditary.com/dosage-information/dalfopristin-quinupristin-dosage-7780.html

Dalfopristin / Quinupristin Dosage

Drug Detail:Dalfopristin and quinupristin (Dalfopristin and quinupristin [ dal-foe-pris-tin-and-kwi-nyoo-pris-tin ])

Drug Class: Streptogramins

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Skin or Soft Tissue Infection

Complicated: 7.5 mg/kg IV every 12 hours, infused over 1 hour

Usual Adult Dose for Bacteremia

Vancomycin-resistant Enterococcus faecium infection: 7.5 mg/kg IV every 8 hours, infused over 1 hour

This indication is no longer approved by the FDA. The submitted data failed to confirm clinical benefit for this condition.

Usual Pediatric Dose for Skin or Soft Tissue Infection

Less than 12 years: Data not available
12 to less than 18 years: 7.5 mg/kg IV every 12 hours, infused over 1 hour

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Data from clinical trials suggest that the incidence of adverse effects in patients with chronic liver insufficiency or cirrhosis was comparable to that in patients with normal hepatic function. Pharmacokinetic data in patients with hepatic cirrhosis (Child Pugh A or B) suggest that dosage reduction may be necessary but exact recommendations cannot be made at this time.

Precautions

Clostridium difficile associated diarrhea (CDAD) has been reported with almost all antibiotics and may potentially be life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea following dalfopristin-quinupristin therapy. Mild cases generally improve with discontinuation of the drug, while severe cases may require supportive therapy and treatment with an antimicrobial agent effective against C difficile. Hypertoxin producing strains of C difficile cause increased morbidity and mortality; these infections can be resistant to antimicrobial treatment and may necessitate colectomy.

Dalfopristin-quinupristin is a major inhibitor of CYP450 3A4. If concurrently administered drugs are substrates of this isoenzyme and have narrow therapeutic windows, their levels should be monitored, and substrates that prolong the QTc interval should be avoided.

Dalfopristin-quinupristin should not be administered as a bolus due to the potential for increased toxicity. It should be infused over 60 minutes. There are no data on the safety of other infusion durations. Animal toxicity was higher with bolus administration compared to slow infusion.

To minimize venous irritation, a peripheral infusion should be followed by a flush with 5% dextrose in water. Saline and heparin are incompatible and should not be used for dilution or flushing. If moderate to severe venous irritation occurs with peripheral infusions of 250 mL, increasing the infusion volume to 500 mL or 750 mL, changing the infusion site, or infusing via a PICC line or central venous catheter should be considered.

Cases of arthralgia and myalgia, some severe, have been reported in with dalfopristin-quinupristin. Some patients showed improvement after reducing the dose frequency to every 12 hours. Symptoms resolved after treatment was discontinued in those patients available for follow-up.

Use of antibiotics may result in superinfections of nonsusceptible organisms. Appropriate measures should be taken if superinfection occurs during therapy.

To reduce the risk of development of drug-resistant organisms, antibiotics should only be used to treat or prevent proven or suspected infections caused by bacteria.

Safety and efficacy have not been established in pediatric patients less than 16 years of age.

Dialysis

No adjustment recommended.

Other Comments

The dosage is expressed in terms of combined "mg" of dalfopristin plus quinupristin.

The minimum recommended treatment duration for complicated skin and skin structure infections is 7 days.

Share this Article
Latest News
Medical News

Seed oils: Omega-6 fatty acids may lower diabetes, heart disease risk

Jun 01, 2025
Type 2 diabetes: Sugary drinks may significantly raise risk
COVID-19: Who do the new vaccine guideline changes affect?
Vitamin D supplements may help slow down aging by 3 years
Aging: Exercise timing, consistency can affect heart and lung fitness
Heart health: Exercise not enough to offset effects of poor sleep
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by